Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?
- 30 June 2005
- journal article
- Published by Elsevier BV in Fertility and Sterility
- Vol. 83 (6), 1607-1611
- https://doi.org/10.1016/j.fertnstert.2005.02.011
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization–embryo transferFertility and Sterility, 2004
- Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonistsFertility and Sterility, 2004
- Premenstrual administration of gonadotropin-releasing hormone antagonist coordinates early antral follicle sizes and sets up the basis for an innovative concept of controlled ovarian hyperstimulationFertility and Sterility, 2004
- Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization–embryo transfer patientsFertility and Sterility, 2004
- Reproductive biology and IVF: ovarian stimulation and endometrial receptivityTrends in Endocrinology & Metabolism, 2004
- Initiation of the gonadotropin-releasing hormone antagonist ganirelix for in vitro fertilization cycles in which the lead follicle is >14 mmFertility and Sterility, 2004
- Contemporary Pharmacological Manipulation in Assisted ReproductionDrugs, 2004
- GnRH antagonistsFertility and Sterility, 2000
- Gonadotrophin-Releasing Hormone AgonistsDrugs, 1994
- INDUCTION OF OVULATION FOR IN-VITRO FERTILISATION USING BUSERELIN AND GONADOTROPINSThe Lancet, 1984